237 related articles for article (PubMed ID: 38139353)
21. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
22. Leptin induces cell proliferation and reduces cell apoptosis by activating c-myc in cervical cancer.
Yuan Y; Zhang J; Cai L; Ding C; Wang X; Chen H; Wang X; Yan J; Lu J
Oncol Rep; 2013 Jun; 29(6):2291-6. PubMed ID: 23588620
[TBL] [Abstract][Full Text] [Related]
23. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
24. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
25. Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression.
Chen D; Kon N; Zhong J; Zhang P; Yu L; Gu W
Mol Cell; 2013 Jul; 51(1):46-56. PubMed ID: 23747016
[TBL] [Abstract][Full Text] [Related]
26. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
Link JM; Hurlin PJ
Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
[TBL] [Abstract][Full Text] [Related]
27. Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Sumi K; Kasahara T; Tago K
PLoS One; 2013; 8(1):e52844. PubMed ID: 23300995
[TBL] [Abstract][Full Text] [Related]
28. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes.
Gartel AL; Shchors K
Exp Cell Res; 2003 Feb; 283(1):17-21. PubMed ID: 12565816
[TBL] [Abstract][Full Text] [Related]
30. Wogonin has multiple anti-cancer effects by regulating c-Myc/SKP2/Fbw7α and HDAC1/HDAC2 pathways and inducing apoptosis in human lung adenocarcinoma cell line A549.
Chen XM; Bai Y; Zhong YJ; Xie XL; Long HW; Yang YY; Wu SG; Jia Q; Wang XH
PLoS One; 2013; 8(11):e79201. PubMed ID: 24265759
[TBL] [Abstract][Full Text] [Related]
31. Dose-dependent regulation of target gene expression and cell proliferation by c-Myc levels.
Schuhmacher M; Eick D
Transcription; 2013; 4(4):192-7. PubMed ID: 23989662
[TBL] [Abstract][Full Text] [Related]
32. Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice.
Factor V; Oliver AL; Panta GR; Thorgeirsson SS; Sonenshein GE; Arsura M
Hepatology; 2001 Jul; 34(1):32-41. PubMed ID: 11431731
[TBL] [Abstract][Full Text] [Related]
33. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
34. Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation.
Amicone L; Terradillos O; Calvo L; Costabile B; Cicchini C; Della Rocca C; Lozupone F; Piacentini M; Buendia MA; Tripodi M
Oncogene; 2002 Feb; 21(9):1335-45. PubMed ID: 11857077
[TBL] [Abstract][Full Text] [Related]
35. Gene Transactivation and Transrepression in MYC-Driven Cancers.
Scafuro M; Capasso L; Carafa V; Altucci L; Nebbioso A
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801599
[No Abstract] [Full Text] [Related]
36. Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity.
Zhang Q; Spears E; Boone DN; Li Z; Gregory MA; Hann SR
Proc Natl Acad Sci U S A; 2013 Jan; 110(3):978-83. PubMed ID: 23277542
[TBL] [Abstract][Full Text] [Related]
37. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
38. MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.
Stefan E; Bister K
Curr Top Microbiol Immunol; 2017; 407():117-151. PubMed ID: 28466200
[TBL] [Abstract][Full Text] [Related]
39. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
40. The many roles of c-Myc in apoptosis.
Thompson EB
Annu Rev Physiol; 1998; 60():575-600. PubMed ID: 9558477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
